ResMed (RMD - Snapshot Report) reached its all-time high of $42.92 on December 12, riding on growing demand for sleep therapy products worldwide and a robust fiscal first-quarter performance. These solid results boosted all 8 estimates for fiscal 2013 over the past 60 days. Consequently, the stock attained a Zacks #1 Rank (Strong Buy) on December 18.
ResMed (RMD - Snapshot Report) reached its all-time high of $42.92 on December 12, riding on growing demand for sleep therapy products worldwide and a robust fiscal first-quarter performance. These solid results boosted all 8 estimates for fiscal 2013 over the past 60 days. Consequently, the stock attained a Zacks #1 Rank (Strong Buy) on December 18.
Share this Article
Recommended